Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | USP19 | O94966 | 4/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507123 | 0.87 | CCR5 (0.44) | CYP2C9SIGMAR1USP19 | |
| SCHEMBL3509723 | 0.83 | OPRD1 (0.39) | SIGMAR1TRPA1 | |
| SCHEMBL2451570 | 0.82 | SIGMAR1 (0.44) | SIGMAR1 | |
| SCHEMBL2451634 | 0.81 | EPHX2 (0.44) | EPHX2HRH3CYP2C9SIGMAR1EPHX1 | |
| SCHEMBL2453500 | 0.80 | SIGMAR1 (0.53) | SIGMAR1 | |
| SCHEMBL2449728 | 0.78 | SIGMAR1 (0.48) | EPHX2HRH3CYP2C9SIGMAR1EPHX1 | |
| SCHEMBL2451492 | 0.78 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL12184675 | 0.77 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL2452588 | 0.77 | EPHX2 (0.55) | EPHX2CYP2C9SIGMAR1EPHX1SCN5A | |
| SCHEMBL2449723 | 0.76 | CCR5 (0.48) | HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | EPHX2 1180/4885HRH3 61/4885CYP2C9 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.